Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin for bacterial infection prevention after allogeneic HSCT
NCT00324324Phase 3Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2006
- Primary completion
- Apr 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of moxifloxacin in bacterial infection, sponsored by OHSU Knight Cancer Institute. Started May 2006; status: terminated.
02
Drugs
moxifloxacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT00324324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324324.